PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

FORTA-Based Pharmacist Review Cuts Medication Problems in Older Cancer Patients

FORTA listmedication reviewdeprescribingpolypharmacypotentially inappropriate medicationsgeriatric oncologyproton pump inhibitorsNSAIDsbeta blockersvaccinationrandomized controlled trialOPTIMAL trialpharmacist-led intervention Ambulatory Care / MTM

Background Information

Pharmacist-led reviews reduce inappropriate medication in older cancer patients.

Older cancer patients often experience polypharmacy, leading to medication-related issues. Improving medication quality can enhance their overall care. The pharmacist-led medication review resulted in a mean FORTA score reduction of 3.7 points and decreased inappropriate medication, underuse, and overuse by 41.3%, 35.5%, and 30.7%, respectively. This study supports pharmacist-led interventions using the FORTA list to optimize medication regimens in older cancer patients, improving safety and efficacy. Pharmacist-led medication reviews significantly improve medication quality in older cancer patients with polypharmacy.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Degen M, Kopp-Schneider A, Vlaski T, Carlsson S, Hallermann P, Jewlanowa L, Barinoff J, Goede V, Lüders C, Kiefer-Trendelenburg T, Lüftner D, Doll J, Wagner J, Leibbrand B, Brenner H, Schöttker B

Citation: Degen M, Kopp-Schneider A, Vlaski T, et al. Cancer co-medication quality in older patients with polypharmacy: A large randomized trial testing a medication review versus usual care. Journal of internal medicine. 2026;300(6):802-820. doi:10.1111/joim.70161

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.